Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.

NCT00517868 is registered in ClinicalTrials.gov with Urigen as lead sponsor.

NCT NCT00517868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00517868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
URG101 Pharmacodynamic and Safety Study: A Randomized, Double-blind, Placebo-controlled, Multi-center Cross-over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.
Lead sponsor
Urigen
Phase
Phase 2
Overall status
Terminated
Start date
August 28, 2007
Completion date
February 28, 2008
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder pain syndrome, interstitial cystitis, painful bladder syndrome